New Hirings, Big Firings Give Intel Stock (NASDAQ:INTC) a Hefty Surge
Chip stock Intel (INTC) has had a fairly rough time with its employees of late, what with firing so many of them in rapid fashion. And the latest set of firings comes with some unexpected word about severance packages: there are none. Meanwhile, a few new hires are getting in on the action in a bid to turn things around at Intel. This was good enough for investors, though, who sent Intel shares on the rise nearly 3% in Wednesday afternoon's trading.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
We remember that Intel plans to lay off about one person in every five from the manufacturing division, which adds up to somewhere around 10,000 employees in total, reports noted. But, in perhaps a rougher note still, reports noted that there will be neither 'voluntary buyouts' nor 'early retirement packages' offered. Rather, Intel will be firing employees '…based on performance evaluations and strategic priorities,' reports noted.
This is the third major round of layoffs Intel has posted so far in the last 12 months, reports note, and has seen everyone from top-level brass to middle management tossed out in a bid to streamline operations. But now, with the factory floor about to take a layoff with nothing more than the shirts on their collective back, the blows will hit throughout the entire operation.
Not Everybody is Fired
And, as we also heard previously, Intel is looking to beef up its engineering ranks to try and develop the next big things in processor development. With Intel looking to get back market share lost to several different competitors, this is perhaps the most clearly urgent course of action for Intel.
Intel recently picked up three 'chip industry executives,' reports noted, who would be tasked with engineering roles, as well as networking roles, within Intel. The new hires come from substantial engineering backgrounds, serving as part of a 'flattened' leadership team. One of them will be running a newly-minted 'customer engineering center,' while another will handle development of an artificial intelligence (AI)-focused system-on-a-chip (SoC) development. The third will handle development duties on new chip architectures, helping to keep Intel in the hunt for the t op slot in the market.
Is Intel a Buy, Hold or Sell?
Turning to Wall Street, analysts have a Hold consensus rating on INTC stock based on one Buy, 26 Holds and four Sells assigned in the past three months, as indicated by the graphic below. After a 32.07% loss in its share price over the past year, the average INTC price target of $21.30 per share implies 0.44% downside risk.
See more INTC analyst ratings
Disclosure
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
33 minutes ago
- National Post
Canada won't pause digital services tax despite pressure from U.S., finance minister says
OTTAWA — Canada won't put a hold on the digital services tax on big tech companies set to take effect on June 30, the finance minister said Thursday. Article content Article content Finance Minister Francois-Philippe Champagne said Thursday the legislation was passed by Parliament and Canada is 'going ahead' with the tax. Article content Article content 'The (digital services tax) is in force and it's going to be applied,' he told reporters before a cabinet meeting on Parliament Hill. Article content Article content It will apply retroactively, leaving U.S. companies with a $2 billion US bill due at the end of the month. A June 11 letter signed by 21 members of Congress said U.S. companies will pay 90 per cent of the revenue Canada will collect from the tax. Article content Canadian and U.S. business groups, organizations representing U.S. tech giants and American members of Congress have all signed letters in recent weeks calling for the tax to be eliminated or paused. Article content It's set to take effect just weeks before a deadline Canada and the U.S. have set for coming up with a new trade deal, following months of trade conflict between the two countries. Article content Rick Tachuk, president of the American Chamber of Commerce in Canada, said the plan to go ahead with the tax 'undercuts those talks and risks derailing the agreement.' Article content Article content 'A retroactive tax like the DST, weeks before a new deal is supposed to be done, isn't a bargaining chip. It would likely be viewed as a provocation,' he said in an emailed statement. Article content Article content The Canadian Chamber of Commerce and other organizations have warned retaliatory measures in a U.S. spending and tax bill could hit Canadians' pension funds and investments. Article content Champagne said Canada isn't the only country that could be affected by those retaliatory measures. Article content David Pierce, the Canadian Chamber of Commerce's vice-president of government relations, said in an earlier interview his organization fears Canada could 'aggravate an already very tricky trade discussion with the Americans' if it goes ahead with the tax and the retroactive payment requirement. Article content Matthew Holmes, the chamber's executive vice-president and chief of public policy, said in a statement that a Liberal government announcement on counter-tariffs to protect the steel and aluminum industries Thursday was 'geared toward the 30-day deadline, so we see no reason why DST's timeline shouldn't be as well.'
CTV News
an hour ago
- CTV News
Higher water bills sinking in for Winnipeg homeowners
The City of Winnipeg has upped its rates for water and sewer services and people are seeing the jump in their bills. CTV's Jeff Keele reports. Bernie Lemanski rarely waters his grass, and when he does, there's not much of a yard anyway. He lives with his brother and their water usage is low. 'The only thing you do is the dishwasher, washer and dryer and a shower,' said Lemanski. So it was sticker shock when he opened his quarterly water bill from the City of Winnipeg. 'I was just flabbergasted, in shock, like I couldn't believe it,' he said. Last quarter he paid $157 dollars and this quarter the bill is $269 dollars. 'Give me a break,' said Lemanski. 'What are they thinking?' Other homeowners are flooding Facebook with comments too, many asking the same question as Lemanski. 'I'd like to know why, why they increased it that high,' he said. Winnipeg's water and waste committee chair Ross Eadie says some people missed the discussion and debate around this issue at City Hall this year. 'It is catching people off guard,' said Eadie. In March, city council approved new sewer and water rate hikes to help fund the $3 billion north sewage treatment plant. There is also a new levy. A $23 per quarter fee was eliminated, but replaced with a higher $63 per quarter waste management fee, to pay for services like garbage, recycling, green carts, yard waste and damaged carts. It's a new utility model to take the heat off property tax bills. 'For the waste management we looked at here's what the cost is, we have contractors who pick up and collect your garbage and there's all kinds of costs related to it,' said Eadie. Things could have been worse. The mayor and council rejected a proposal to jack water and sewer rates by a $1,000 a year for a family of four. Still, Lemanski says the approved rates and fees are tough to swallow. 'A lot of single parents and they're on their own and they're living on a fixed income and they can't afford this kind of increase.'
Globe and Mail
an hour ago
- Globe and Mail
Blood Cell Factors Market Expected to Touch USD 4.31 Bn by 2032, CAGR of 3.6% Detailed in New Report
The global blood cell factors market growth is driven by the increasing prevalence of blood disorders, advancements in healthcare infrastructure, and rising demand for effective treatments. Additionally, growing awareness about blood cell factors and their role in treating various blood-related conditions are expected to fuel the market growth. Blood Cell Factors Market Insights The Blood Cell Factors industry is experiencing robust expansion driven by rising hemophilia treatment demand and novel biologics pipelines. This expert analysis explores market size, dynamics, and actionable insights to guide strategic decision-making in 2025–2032. The Global Blood Cell Factors Market size is estimated to be valued at USD 3.37 Bn in 2025 and is expected to reach USD 4.31 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032. According to the latest Blood Cell Factors market size assessment and Blood Cell Factors market report, global market revenue surpassed USD 3.4 Bn in 2024, indicating an upward shift in market share across major regions. This market forecast underscores expanding industry size and business growth opportunities. Market Key Takeaways: Region: • North America: Strong R&D investments in recombinant factors drive advanced product launches. • Latin America: Rising healthcare infrastructure improvements accelerate treatment adoption. • Europe: Regulatory harmonization fosters cross-border supply chains. • Asia Pacific: Expanding manufacturing capacity and favorable pricing boost volume. • Middle East: Government-backed hemophilia programs underpin demand growth. • Africa: Emerging import channels and NGO support enhance access. Segment Covers: • Product Type: – Recombinant Factors: Example: Amgen's 2024 launch of Factor VIII rAHFV captured 42% of new biologics uptake. – Plasma-Derived Factors: Sanofi's Purified FVIII retains stable pricing leadership in 2025. – Gene Therapy Platforms: Early-stage pipelines by Regeneron target one-dose cures. • Application: – Hemophilia A/B: Eli Lilly's factor IX pegylated formulation grew 28% in 2024 revenues. – Von Willebrand Disease: Pfizer's new multi‐domain VWF therapy gained EMA approval in 2024. • End User: – Hospitals & Clinics: Accounted for 65% of procurement in 2024. – Specialty Centers: Focused infusion protocols drive repeat purchase patterns. Growth Factors: • Rising Prevalence of Coagulation Disorders: The global hemophilia population increased by 4.5% between 2023 and 2024, driving factor consumption. • Strategic Partnerships: In 2024, Roche's collaboration with a biotech startup increased manufacturing capacity by 15% and expanded contract manufacturing revenue by USD 80 Mn. • Blood Cell Factors market share gains hinge on targeted rebates and patient support programs in North America and Europe, lifting volume growth despite pricing pressures. • Increased public funding for rare diseases in Japan and Australia boosted factor adoption by 12% in 2024. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: • Personalized Medicine: Tailored dosing algorithms using AI-driven pharmacokinetic models reduced bleed rates by 30% in 2024 trials. • Biosimilar Entrants: Novartis's pipeline biosimilar of FVIII (expected 2025 launch) is projected to undercut reference pricing by 20%. • Digital Adherence Tools: Mobile infusion tracking apps improved on-time dosing by 18% across 2024 real-world studies. • Blood Cell Factors market trends indicate heightened M&A activity—with Teva's acquisition of a plasma facility in 2024 enhancing Asia Pacific supply by 25%. Actionable Insights: • Production Capacity: Global recombinant factor capacity rose to 150 kg in 2024, up 10% YOY, enabling wider supply. • Pricing Benchmarks: Median USD 0.85/IU for FVIII in Western Europe vs. USD 0.65/IU in Asia Pacific illustrates import-driven discounts. • Exports & Imports: Asia Pacific exported USD 220 Mn of plasma-derived factors in 2024, while Africa imported USD 90 Mn, reflecting demand-supply gaps. • Use-Case Volumes: Hospital procurement volumes for prophylactic regimens grew 14% in Latin America in 2024, outpacing on-demand therapy. • Nano-Indicators: Patient registry expansions in the Middle East added 5,000 new documented cases in 2024, informing localized forecasting models. • Blood Cell Factors market revenue analyses highlight cost-per-patient as a leading macro-indicator for future investment. Key Players: • Amgen Inc. • Johnson & Johnson • Roche Holding AG • Novartis AG • Pfizer Inc. • Bristol-Myers Squibb Company • Eli Lilly Company • Gilead Sciences Inc. • Sanofi S.A. • Merck & Co. Inc. • Teva Pharmaceutical Industries Ltd. • AbbVie Inc. • Celgene Corporation • Takeda Pharmaceutical Company Limited • Regeneron Pharmaceuticals Inc. Get Customization on this Report: Competitive Strategies: – Roche's 2024 capacity partnership with Biogen boosted contract revenues by USD 80 Mn and reduced production costs by 12%. – Novartis's biosimilar rollout strategy undercut reference FVIII pricing by 20%, capturing 8% market share in Europe within six months. – Pfizer's bundled care agreements with specialty clinics in North America in 2024 increased annualized purchases by 22%. Frequently Asked Questions 1. Who are the dominant players in the Blood Cell Factors market? Major players include Amgen, Roche, Novartis, Pfizer, and Sanofi, each commanding significant market share through diversified portfolios and strategic alliances. 2. What will be the size of the Blood Cell Factors market in the coming years? The market is forecast to grow from USD 3.37 Bn in 2025 to USD 4.31 Bn by 2032 at a 3.6% CAGR. 3. Which end-user industry has the largest growth opportunity? Hospitals & clinics represent the largest segment, accounting for over 65% of revenues in 2024, driven by prophylactic treatment mandates. 4. How will market development trends evolve over the next five years? Trends include AI-enabled dosing, gene therapy maturation, and biosimilar price competition, reshaping market dynamics and business growth strategies. 5. What is the nature of the competitive landscape and challenges in the Blood Cell Factors market? Intense R&D races, biosimilar threats, and supply-chain complexities define the competitive landscape, while high manufacturing costs remain a key restraint. 6. What go-to-market strategies are commonly adopted in the Blood Cell Factors market? Strategies include co-development partnerships, patient support services, value-based contracts, and digital adherence platforms to drive uptake and retention. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
